Watson-Kissei’s Silodosin For BPH Could Have Oct. 14 User Fee Date
This article was originally published in The Pink Sheet Daily
FDA accepts Watson-Kissei’s NDA for silodosin to treat benign prostatic hyperplasia.
You may also be interested in...
Silodosin would take on GSK’s Avodart and Pfizer’s Cardura XL.
Drug manufacturers made a pledge to contribute $80 bil. in a mix of savings and revenue-raising initiatives to help fund health reform. In return, they could see a wide range of new business depending on how you look at the numbers.
Despite voting that King's CorVu is not equivalent to its study comparator, Cardio-Renal panel sees bright future for the stress agent.